Status:
COMPLETED
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
Carmot Therapeutics, Inc.
Collaborating Sponsors:
Carmot Australia First Pty Ltd
Conditions:
Diabetes
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise health...
Eligibility Criteria
Inclusion
- Males or females
- 18-65 years old, inclusive
- BMI 27.0-40.0, inclusive
- Stable body weight for 2 months
Exclusion
- Significant medical history
- Uncontrolled hypertension
- History of malignancy
Key Trial Info
Start Date :
April 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 2 2024
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT04838405
Start Date
April 29 2021
End Date
August 2 2024
Last Update
October 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Carmot Clinical Research Unit 101
Perth, Western Australia, Australia, 6009
2
Carmot Clinical Research Unit 105
Monterrey, Nuevo León, Mexico, 66260